Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorLeipzig Heart Science gGmbH
About this trial
Prospective, randomized, controlled, multicenter, open-label trial to study whether multivessel percutaneous coronary intervention (PCI) is superior over culprit-lesion only PCI in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease.
Eligibility criteria
Qualifiers
NSTEMI as suggested by high-sensitivity troponin algorithms
Multivessel coronary artery disease
Identifiable culprit lesion
Informed consent
Disqualifiers
Age <18 years
Cardiogenic shock
Sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)
Contraindication for coronary revascularization
Trial design
Treatments tested in this trial
- Culprit-lesion revascularization
- Non-culprit-lesion revascularization
Treatment groups
3,390 Participants
are divided into 2 treatment groupsSponsors and collaborators
Leipzig Heart Science gGmbH
Lead sponsor
Heart Center Leipzig at University of Leipzig
Collaborator
German Federal Ministry of Education and Research
Collaborator
IHF GmbH - Institut für Herzinfarktforschung
Collaborator
Stiftung IHF - Institut für Herzinfarktforschung
Collaborator
Source ClinicalTrials.gov